Physician profile
James C Greenfield
NPI 1396700845
$20,289.75
in general payments reported to CMS, 2019-2025
36 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $581 · 2021: $926 · 2022: $8,691 · 2023: $5,301 · 2024: $2,553 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,850 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,800 · Travel and Lodging: $60.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,850.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,800.00 |
| Travel and Lodging | $60.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,395.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,586.19 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,101.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $698.95 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $632.08 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $418.94 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Braeburn INC. | $357.92 | 2023-2025 | Brixadi |
| Alkermes, INC. | $346.29 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Indivior INC. | $307.67 | 2019-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $296.54 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $287.67 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Amgen INC. | $256.53 | 2022-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $244.00 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Exact Sciences Corporation | $170.27 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $151.64 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.99 | 2019-2023 | Jardiance |
| Allergan, INC. | $126.99 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $116.53 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $84.93 | 2023-2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $63.76 | 2022-2023 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $57.74 | 2024-2025 | Fanapt |
| Verona Pharma, INC. | $52.68 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $51.48 | 2021-2022 | |
| Astellas Pharma US INC | $50.66 | 2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $42.20 | 2021 | |
| Lundbeck LLC | $36.20 | 2021-2023 | Rexulti |
| Medtronic, INC. | $36.01 | 2021-2022 | |
| Philips North America LLC | $29.95 | 2019-2020 | |
| Amarin Pharma, INC. | $29.05 | 2020-2021 | |
| Pfizer INC. | $28.56 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.41 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $17.13 | 2019 | |
| Owp Pharmaceuticals, INC. | $16.63 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.50 | 2022 | |
| Zealand Pharma US, INC. | $13.59 | 2021 | |
| Medtronic Minimed, INC. | $12.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Greenfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.